Market Overview

Impax Labs Enters Commercialization Deal with Perrigo

Related PRGO
Top Performing Industries For November 24, 2014
Perrigo Acquires Omega Pharma For $4.5 Billion Euro
Horizon Inks $660M Reverse Merger With Ireland's Vidara (Fox Business)
Related IPXL
8 Attractive U.S. Healthcare Stocks With Low PEG Ratios
Teva Beats Q3 Earnings Expectations, Updates Outlook
Middle-Market Deal Making Surges in First Three Quarters (Fox Business)

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that it will collaborate with Perrigo Company (NASDAQ: PRGO;TASE) on the development, manufacturing and commercialization of an extended topical generic drug product with first to market potential. The product and terms of the agreement were not disclosed.

Posted-In: News


Related Articles (IPXL + PRGO)

Around the Web, We're Loving...

Get Benzinga's Newsletters